Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 561

1.

Key considerations in the pharmacotherapy of tuberculous meningitis.

Wasserman S, Davis A, Wilkinson RJ, Meintjes G.

Expert Opin Pharmacother. 2019 Jul 15:1-5. doi: 10.1080/14656566.2019.1638912. [Epub ahead of print] No abstract available.

PMID:
31305179
2.

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.

Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL, Wasserman SM, Deedwania P, Olsson AG, Sever PS, Keech AC, Giugliano RP; FOURIER Steering Committee and Investigators.

J Am Coll Cardiol. 2019 Jun 18;73(23):2961-2970. doi: 10.1016/j.jacc.2019.03.513.

PMID:
31196453
3.

Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa.

Wasserman S, Louw G, Ramangoaela L, Barber G, Hayes C, Omar SV, Maartens G, Barry C, Song T, Meintjes G.

J Antimicrob Chemother. 2019 May 12. pii: dkz206. doi: 10.1093/jac/dkz206. [Epub ahead of print]

PMID:
31081017
4.

The Contribution of Host Cells to Pneumocystis Immunity: An Update.

Otieno-Odhiambo P, Wasserman S, Hoving JC.

Pathogens. 2019 Apr 19;8(2). pii: E52. doi: 10.3390/pathogens8020052. Review.

5.

Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy.

Chan DC, Watts GF, Coll B, Wasserman SM, Marcovina SM, Barrett PHR.

J Am Heart Assoc. 2019 Apr 2;8(7):e011781. doi: 10.1161/JAHA.118.011781.

6.

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety.

Lee E, Gibbs JP, Emery MG, Block G, Wasserman SM, Hamilton L, Kasichayanula S, Hanafin P, Somaratne R, Egbuna O.

Clin Pharmacol Drug Dev. 2019 Apr;8(3):281-289. doi: 10.1002/cpdd.650. Epub 2019 Jan 24.

7.

Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer.

Hamza B, Ng SR, Prakadan SM, Delgado FF, Chin CR, King EM, Yang LF, Davidson SM, DeGouveia KL, Cermak N, Navia AW, Winter PS, Drake RS, Tammela T, Li CM, Papagiannakopoulos T, Gupta AJ, Shaw Bagnall J, Knudsen SM, Vander Heiden MG, Wasserman SC, Jacks T, Shalek AK, Manalis SR.

Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2232-2236. doi: 10.1073/pnas.1814102116. Epub 2019 Jan 23.

8.

Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection.

Wasserman S, Denti P, Brust JCM, Abdelwahab M, Hlungulu S, Wiesner L, Norman J, Sirgel FA, Warren RM, Esmail A, Dheda K, Gandhi NR, Meintjes G, Maartens G.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02164-18. doi: 10.1128/AAC.02164-18. Print 2019 Mar.

PMID:
30617089
9.

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.

O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS.

Circulation. 2019 Mar 19;139(12):1483-1492. doi: 10.1161/CIRCULATIONAHA.118.037184.

10.

Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.

Stiekema LCA, Stroes ESG, Verweij SL, Kassahun H, Chen L, Wasserman SM, Sabatine MS, Mani V, Fayad ZA.

Eur Heart J. 2018 Dec 18. doi: 10.1093/eurheartj/ehy862. [Epub ahead of print]

PMID:
30561610
11.

Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.

Qamar A, Giugliano RP, Keech AC, Kuder JF, Murphy SA, Kurtz CE, Wasserman SM, Sever PS, Pedersen TR, Sabatine MS.

JAMA Cardiol. 2019 Jan 1;4(1):59-63. doi: 10.1001/jamacardio.2018.4178.

PMID:
30540337
12.

Regulation of SH3PX1 by dNedd4-long at the Drosophila neuromuscular junction.

Wasserman SS, Shteiman-Kotler A, Harris K, Iliadi KG, Persaud A, Zhong Y, Zhang Y, Fang X, Boulianne GL, Stewart B, Rotin D.

J Biol Chem. 2019 Feb 1;294(5):1739-1752. doi: 10.1074/jbc.RA118.005161. Epub 2018 Dec 5.

PMID:
30518551
13.

The diagnosis of hereditary angioedema with C1 inhibitor deficiency: a survey of Canadian physicians and laboratories.

Charest-Morin X, Betschel S, Borici-Mazi R, Kanani A, Lacuesta G, Rivard GÉ, Wagner E, Wasserman S, Yang B, Drouet C.

Allergy Asthma Clin Immunol. 2018 Nov 21;14:83. doi: 10.1186/s13223-018-0307-0. eCollection 2018.

14.

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.

Gong X, Du J, Parsons SH, Merzoug FF, Webster Y, Iversen PW, Chio LC, Van Horn RD, Lin X, Blosser W, Han B, Jin S, Yao S, Bian H, Ficklin C, Fan L, Kapoor A, Antonysamy S, Mc Nulty AM, Froning K, Manglicmot D, Pustilnik A, Weichert K, Wasserman SR, Dowless M, Marugán C, Baquero C, Lallena MJ, Eastman SW, Hui YH, Dieter MZ, Doman T, Chu S, Qian HR, Ye XS, Barda DA, Plowman GD, Reinhard C, Campbell RM, Henry JR, Buchanan SG.

Cancer Discov. 2019 Feb;9(2):248-263. doi: 10.1158/2159-8290.CD-18-0469. Epub 2018 Oct 29.

PMID:
30373917
15.

Effect of Evolocumab on Coronary Plaque Composition.

Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Honda S, Shishikura D, Scherer DJ, Borgman M, Brennan DM, Wolski K, Nissen SE.

J Am Coll Cardiol. 2018 Oct 23;72(17):2012-2021. doi: 10.1016/j.jacc.2018.06.078.

PMID:
30336824
16.

Erratum to South African guideline for the management of community-acquired pneumonia in adults.

Boyles TH, Brink A, Calligaro GL, Cohen C, Dheda K, Maartens G, Richards GA, van Zyl Smit R, Smith C, Wasserman S, Whitelaw AC, Feldman C; South African Thoracic Society; Federation of Infectious Diseases Societies of Southern Africa.

J Thorac Dis. 2018 Aug;10(8):E673-E675. doi: 10.21037/jtd.2018.07.137.

17.

Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.

Zhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N, Leslie J, Boulle A, Mudaly V, Kock Y, Meintjes G, Wasserman S.

Clin Infect Dis. 2019 Apr 24;68(9):1522-1529. doi: 10.1093/cid/ciy727.

PMID:
30165431
18.

Diversity of visuomotor reflexes in two Drosophila species.

Park EJ, Wasserman SM.

Curr Biol. 2018 Aug 20;28(16):R865-R866. doi: 10.1016/j.cub.2018.06.071.

PMID:
30130502
19.

The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research.

Walker NF, Stek C, Wasserman S, Wilkinson RJ, Meintjes G.

Curr Opin HIV AIDS. 2018 Nov;13(6):512-521. doi: 10.1097/COH.0000000000000502.

20.

Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies.

Stroes E, Robinson JG, Raal FJ, Dufour R, Sullivan D, Kassahun H, Ma Y, Wasserman SM, Koren MJ.

Clin Cardiol. 2018 Oct;41(10):1328-1335. doi: 10.1002/clc.23049. Epub 2018 Oct 21.

21.

Outcomes of HIV-associated pneumocystis pneumonia at a South African referral hospital.

Chiliza N, Du Toit M, Wasserman S.

PLoS One. 2018 Aug 2;13(8):e0201733. doi: 10.1371/journal.pone.0201733. eCollection 2018.

22.

Short-Form Bomanins Mediate Humoral Immunity in Drosophila.

Lindsay SA, Lin SJH, Wasserman SA.

J Innate Immun. 2018;10(4):306-314. doi: 10.1159/000489831. Epub 2018 Jun 19.

23.

The management and outcomes of Staphylococcus aureus bacteraemia at a South African referral hospital: A prospective observational study.

Steinhaus N, Al-Talib M, Ive P, Boyles T, Bamford C, Davies MA, Mendelson M, Wasserman S.

Int J Infect Dis. 2018 Aug;73:78-84. doi: 10.1016/j.ijid.2018.06.004. Epub 2018 Jun 13.

24.

Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial.

Martin SS, Giugliano RP, Murphy SA, Wasserman SM, Stein EA, Ceška R, López-Miranda J, Georgiev B, Lorenzatti AJ, Tikkanen MJ, Sever PS, Keech AC, Pedersen TR, Sabatine MS.

JAMA Cardiol. 2018 Aug 1;3(8):749-753. doi: 10.1001/jamacardio.2018.1533.

25.

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.

Chan DC, Watts GF, Somaratne R, Wasserman SM, Scott R, Barrett PHR.

Arterioscler Thromb Vasc Biol. 2018 Jul;38(7):1644-1655. doi: 10.1161/ATVBAHA.118.310882. Epub 2018 Jun 7.

26.

Leveraging electronic health records for clinical research.

Raman SR, Curtis LH, Temple R, Andersson T, Ezekowitz J, Ford I, James S, Marsolo K, Mirhaji P, Rocca M, Rothman RL, Sethuraman B, Stockbridge N, Terry S, Wasserman SM, Peterson ED, Hernandez AF.

Am Heart J. 2018 Aug;202:13-19. doi: 10.1016/j.ahj.2018.04.015. Epub 2018 Apr 30.

PMID:
29802975
27.

Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications.

Wasserman SM, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, Doshi S, Liu T, Somaratne R, Gibbs JP.

J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):423-432. doi: 10.1177/1074248418774043. Epub 2018 May 16.

PMID:
29768954
28.

Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia.

Kuchimanchi M, Grover A, Emery MG, Somaratne R, Wasserman SM, Gibbs JP, Doshi S.

J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):505-522. doi: 10.1007/s10928-018-9592-y. Epub 2018 May 7.

29.

Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.

Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, Barrett PHR.

Eur Heart J. 2018 Jul 14;39(27):2577-2585. doi: 10.1093/eurheartj/ehy122.

PMID:
29566128
30.

Paradoxical worsening of Emergomyces africanus infection in an HIV-infected male on itraconazole and antiretroviral therapy.

Crombie K, Spengane Z, Locketz M, Dlamini S, Lehloenya R, Wasserman S, Maphanga TG, Govender NP, Kenyon C, Schwartz IS.

PLoS Negl Trop Dis. 2018 Mar 8;12(3):e0006173. doi: 10.1371/journal.pntd.0006173. eCollection 2018 Mar. No abstract available.

31.

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor.

Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP.

Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7. Review.

32.

Utilization of peptide phage display to investigate hotspots on IL-17A and what it means for drug discovery.

Ting JP, Tung F, Antonysamy S, Wasserman S, Jones SB, Zhang FF, Espada A, Broughton H, Chalmers MJ, Woodman ME, Bina HA, Dodge JA, Benach J, Zhang A, Groshong C, Manglicmot D, Russell M, Afshar S.

PLoS One. 2018 Jan 12;13(1):e0190850. doi: 10.1371/journal.pone.0190850. eCollection 2018.

33.

New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk.

Graham I, Shear C, De Graeff P, Boulton C, Catapano AL, Stough WG, Carlsson SC, De Backer G, Emmerich J, Greenfeder S, Kim AM, Lautsch D, Nguyen T, Nissen SE, Prasad K, Ray KK, Robinson JG, Sasiela WJ, Bruins Slot K, Stroes E, Thuren T, Van der Schueren B, Velkovski-Rouyer M, Wasserman SM, Wiklund O, Zouridakis E; European Society of Cardiology Cardiovascular Roundtable.

Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):119-127. doi: 10.1093/ehjcvp/pvx031. Review.

PMID:
29194462
34.

AIDS-Related Endemic Mycoses in Western Cape, South Africa, and Clinical Mimics: A Cross-Sectional Study of Adults With Advanced HIV and Recent-Onset, Widespread Skin Lesions.

Schwartz IS, Kenyon C, Lehloenya R, Claasens S, Spengane Z, Prozesky H, Burton R, Parker A, Wasserman S, Meintjes G, Mendelson M, Taljaard J, Schneider JW, Beylis N, Maloba B, Govender NP, Colebunders R, Dlamini S.

Open Forum Infect Dis. 2017 Aug 25;4(4):ofx186. doi: 10.1093/ofid/ofx186. eCollection 2017 Fall.

35.

Itraconazole and antiretroviral therapy: strategies for empirical dosing.

Schwartz IS, Wasserman S.

Lancet Infect Dis. 2017 Nov;17(11):1122-1123. doi: 10.1016/S1473-3099(17)30568-6. No abstract available.

PMID:
29115262
36.

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.

Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators.

Lancet. 2017 Oct 28;390(10106):1962-1971. doi: 10.1016/S0140-6736(17)32290-0. Epub 2017 Aug 28.

37.

Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?

Dheda K, Cox H, Esmail A, Wasserman S, Chang KC, Lange C.

Respirology. 2018 Jan;23(1):36-45. doi: 10.1111/resp.13143. Epub 2017 Aug 29. Review.

38.

Otitis Media and Nasopharyngeal Colonization in ccl3-/- Mice.

Deniffel D, Nuyen B, Pak K, Suzukawa K, Hung J, Kurabi A, Wasserman SI, Ryan AF.

Infect Immun. 2017 Oct 18;85(11). pii: e00148-17. doi: 10.1128/IAI.00148-17. Print 2017 Nov.

39.

Cognitive Function in a Randomized Trial of Evolocumab.

Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman SM, Ott BR; EBBINGHAUS Investigators.

N Engl J Med. 2017 Aug 17;377(7):633-643. doi: 10.1056/NEJMoa1701131.

40.

South African guideline for the management of community-acquired pneumonia in adults.

Boyles TH, Brink A, Calligaro GL, Cohen C, Dheda K, Maartens G, Richards GA, van Zyl Smit R, Smith C, Wasserman S, Whitelaw AC, Feldman C; South African Thoracic Society; Federation of Infectious Diseases Societies of Southern Africa.

J Thorac Dis. 2017 Jun;9(6):1469-1502. doi: 10.21037/jtd.2017.05.31. Review. No abstract available. Erratum in: J Thorac Dis. 2018 Aug;10(8):E673-E675.

41.

Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.

Povsic TJ, Scott R, Mahaffey KW, Blaustein R, Edelberg JM, Lefkowitz MP, Solomon SD, Fox JC, Healy KE, Khakoo AY, Losordo DW, Malik FI, Monia BP, Montgomery RL, Riesmeyer J, Schwartz GG, Zelenkofske SL, Wu JC, Wasserman SM, Roe MT.

Cardiovasc Drugs Ther. 2017 Aug;31(4):445-458. doi: 10.1007/s10557-017-6739-9. Review.

PMID:
28735360
42.

Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism".

Watts GF, Chan DC, Somaratne R, Wasserman SM, Sabatine MS.

Circulation. 2017 Jul 4;136(1):120-121. doi: 10.1161/CIRCULATIONAHA.117.028790. No abstract available.

PMID:
28674100
43.

Obesity's effect on asthma extends to diagnostic criteria.

Lugogo N, Green CL, Agada N, Zhang S, Meghdadpour S, Zhou R, Yang S, Anstrom KJ, Israel E, Martin R, Lemanske RF Jr, Boushey H, Lazarus SC, Wasserman SI, Castro M, Calhoun W, Peters SP, DiMango E, Chinchilli V, Kunselman S, King TS, Icitovic N, Kraft M.

J Allergy Clin Immunol. 2018 Mar;141(3):1096-1104. doi: 10.1016/j.jaci.2017.04.047. Epub 2017 Jun 15.

44.

Allosteric modulation of human dopamine transporter activity under conditions promoting its dimerization.

Cheng MH, Garcia-Olivares J, Wasserman S, DiPietro J, Bahar I.

J Biol Chem. 2017 Jul 28;292(30):12471-12482. doi: 10.1074/jbc.M116.763565. Epub 2017 Jun 5.

45.

South African medical students' perceptions and knowledge about antibiotic resistance and appropriate prescribing: Are we providing adequate training to future prescribers?

Wasserman S, Potgieter S, Shoul E, Constant D, Stewart A, Mendelson M, Boyles TH.

S Afr Med J. 2017 Apr 25;107(5):405-410. doi: 10.7196/SAMJ.2017.v107i5.12370.

46.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators.

N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.

47.

Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies.

Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Djedjos C, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators.

Circulation. 2017 May 9;135(19):1819-1831. doi: 10.1161/CIRCULATIONAHA.116.025233. Epub 2017 Mar 1.

PMID:
28249876
48.

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.

Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA.

Lancet Diabetes Endocrinol. 2017 Apr;5(4):280-290. doi: 10.1016/S2213-8587(17)30044-X. Epub 2017 Feb 16.

PMID:
28215937
49.

Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial.

Giugliano RP, Mach F, Zavitz K, Kurtz C, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Honarpour N, Wasserman SM, Ott BR; EBBINGHAUS Investigators.

Clin Cardiol. 2017 Feb;40(2):59-65. doi: 10.1002/clc.22678. Epub 2017 Feb 16.

50.

Brief Report: Flow Rate of Cerebrospinal Fluid Through a Spinal Needle Can Accurately Predict Intracranial Pressure in Cryptococcal Meningitis.

Boyles TH, Gatley E, Wasserman S, Meintjes G.

J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):e64-e66. doi: 10.1097/QAI.0000000000001183.

PMID:
28187086

Supplemental Content

Loading ...
Support Center